A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk.

@article{Kiyosue2016AP3,
  title={A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk.},
  author={Arihiro Kiyosue and Narimon Honarpour and Christopher E Kurtz and Allen G. Xue and Scott M. Wasserman and A Hirayama},
  journal={The American journal of cardiology},
  year={2016},
  volume={117 1},
  pages={40-7}
}
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This phase 3 study evaluated the efficacy and safety of evolocumab plus atorvastatin in Japanese patients with hyperlipidemia or mixed dyslipidemia and high cardiovascular risk. Patients were randomized to atorvastatin 5 or 20 mg/day for 4 weeks. Subsequently, patients underwent second randomization to evolocumab 140 mg… CONTINUE READING